Pre-therapeutic assessment of plasma dihydrouracil/uracil ratio for predicting the pharmacokinetic parameters of 5-fluorouracil and tumor growth in a rat model of colorectal cancer. 2013

Shinji Kobuchi, and Yukako Ito, and Kae Okada, and Kazuki Imoto, and Shota Kuwano, and Kanji Takada
Department of Pharmacokinetics, Kyoto Pharmaceutical University, Kyoto, Japan. ky05122@poppy.kyoto-phu.ac.jp

We investigated the correlation between plasma ratio of dihydrouracil/uracil (UH2/Ura), a possible surrogate biomarker of hepatic dihydropyrimidine dehydrogenase (DPD) activity, and 5-fluorouracil (5-FU) treatment efficacy in rats with colorectal cancer (CRC). 5-FU pharmacokinetic and pharmacodynamic studies were performed using DPD circadian variation in rats with 1,2-dimethylhydrazine-induced CRC. By plotting tumor volume after 5-FU treatment against pre-therapeutic plasma UH2/Ura, we inferred a linear relationship (r(2)=0.988). 5-FU concentration fluctuations induced by DPD activity variation affected tumor volume. In CRC patients receiving proper dosing regimens, plasma UH2/Ura could be an indirect biomarker for predicting 5-FU treatment efficacy, tumor growth, and 5-FU doses.

UI MeSH Term Description Entries
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008297 Male Males
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000964 Antimetabolites, Antineoplastic Antimetabolites that are useful in cancer chemotherapy. Antineoplastic Antimetabolites
D014498 Uracil One of four nucleotide bases in the nucleic acid RNA.
D015179 Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI. Colorectal Cancer,Colorectal Carcinoma,Colorectal Tumors,Neoplasms, Colorectal,Cancer, Colorectal,Cancers, Colorectal,Carcinoma, Colorectal,Carcinomas, Colorectal,Colorectal Cancers,Colorectal Carcinomas,Colorectal Neoplasm,Colorectal Tumor,Neoplasm, Colorectal,Tumor, Colorectal,Tumors, Colorectal
D017208 Rats, Wistar A strain of albino rat developed at the Wistar Institute that has spread widely at other institutions. This has markedly diluted the original strain. Wistar Rat,Rat, Wistar,Wistar Rats
D042943 Dihydrouracil Dehydrogenase (NADP) An oxidoreductase involved in pyrimidine base degradation. It catalyzes the catabolism of THYMINE; URACIL and the chemotherapeutic drug, 5-FLUOROURACIL. Dihydropyrimidine Dehydrogenase,Dihydrothymine Dehydrogenase (NADP),Dehydrogenase, Dihydropyrimidine
D047368 Tumor Burden The total amount (cell number, weight, size or volume) of tumor cells or tissue in the body. Tumor Load,Tumor Volume,Tumor Weight,Burden, Tumor,Load, Tumor,Loads, Tumor,Tumor Loads,Tumor Weights,Volume, Tumor,Weight, Tumor,Weights, Tumor

Related Publications

Shinji Kobuchi, and Yukako Ito, and Kae Okada, and Kazuki Imoto, and Shota Kuwano, and Kanji Takada
January 2010, The Journal of international medical research,
Shinji Kobuchi, and Yukako Ito, and Kae Okada, and Kazuki Imoto, and Shota Kuwano, and Kanji Takada
April 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Shinji Kobuchi, and Yukako Ito, and Kae Okada, and Kazuki Imoto, and Shota Kuwano, and Kanji Takada
January 2007, Chemotherapy,
Shinji Kobuchi, and Yukako Ito, and Kae Okada, and Kazuki Imoto, and Shota Kuwano, and Kanji Takada
September 2009, Pathologie-biologie,
Shinji Kobuchi, and Yukako Ito, and Kae Okada, and Kazuki Imoto, and Shota Kuwano, and Kanji Takada
January 2013, Biomedical chromatography : BMC,
Shinji Kobuchi, and Yukako Ito, and Kae Okada, and Kazuki Imoto, and Shota Kuwano, and Kanji Takada
March 2004, Gan to kagaku ryoho. Cancer & chemotherapy,
Shinji Kobuchi, and Yukako Ito, and Kae Okada, and Kazuki Imoto, and Shota Kuwano, and Kanji Takada
June 2003, Journal of pharmaceutical sciences,
Shinji Kobuchi, and Yukako Ito, and Kae Okada, and Kazuki Imoto, and Shota Kuwano, and Kanji Takada
April 2022, Clinical chemistry and laboratory medicine,
Shinji Kobuchi, and Yukako Ito, and Kae Okada, and Kazuki Imoto, and Shota Kuwano, and Kanji Takada
October 2014, Cancer chemotherapy and pharmacology,
Shinji Kobuchi, and Yukako Ito, and Kae Okada, and Kazuki Imoto, and Shota Kuwano, and Kanji Takada
July 2002, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences,
Copied contents to your clipboard!